Possibilities and prospects of using immunomodulatory therapy in the treatment of acute respiratory infections in children

Acute respiratory infections (ARI) can be called a global burden of modern pediatrics. The most frequent incidence of ARI, mainly of viral etiology, is experienced by children of the first 6 years of life: infants, as well as children of early and preschool age. This is explained primarily by the physiological characteristics of their immune system. In this regard, the issue of rational selection of an immunotropic drug with proven efficacy and safety, capable of both increasing resistance to infectious agents and increasing the effectiveness of the complex therapy of ARI, especially in the most vulnerable categories of patients from the point of view of the immune response, is becoming relevant. Among the numerous immunomodulatory drugs, a group of bacterial lysates stands out, attracting the attention of practicing physicians and researchers in the context of non-specific immunoprophylaxis and immunotherapy of ARIs. The use of drugs in this spectrum promotes the activation of innate and adaptive links of immunity, faster relief of symptoms of respiratory infection, and also reduces the risk of complications and, accordingly, reduces the need for antibacterial therapy. A special feature of the pharmacological action of this group of drugs is the induction of an adaptive immune response not only against pathogens whose antigens are part of bacterial lysates, but also an increase in resistance to many other bacterial and viral infectious agents. Among bacterial lysates, OM-85 is the leader in terms of evidence – the most studied modulator of anti-infective protection of the respiratory tract. Its effectiveness and safety have been demonstrated in numerous randomized clinical trials. Its effectiveness and safety have been demonstrated in numerous randomized clinical trials. The article presents data confirming the advantages of OM-85 over other immunotropic drugs.

1. Globenko AA, Kuzin GV, Rydlovskaya AV, Isaeva EI, Vetrova EN, Pritchina TN et al. Curtailing virus-induced inflammation in respiratory infections: emerging strategies for therapeutic interventions. Front Pharmacol. 2023;14:1087850. https://doi.org/10.3389/fphar.2023.1087850.

2. Heinonen S, Rodriguez-Fernandez R, Diaz A, Oliva Rodriguez-Pastor S, Ramilo O, Mejias A. Infant Immune Response to Respiratory Viral Infections. Immunol Allergy Clin North Am. 2019;39(3):361–376. https://doi.org/10.1016/j.iac.2019.03.005.

3. Ruzhentsova TA, Meshkova NA, Khavkina DA. Effects of combination therapy with interferon alpha-2b and vitamins E and C on the course of acute respiratory infections and influenza in children: results of meta-analysis. Infectious Diseases. 2020;18(2):68–78. (In Russ.) https://doi.org/10.20953/1729-9225-2020-2-68-78.

4. Kurskaya OG, Prokopyeva EA, Sobolev IA, Solomatina MV, Saroyan TA, Dubovitskiy NA et al. Changes in the Etiology of Acute Respiratory Infections among Children in Novosibirsk, Russia, between 2019 and 2022: The Impact of the SARS-CoV-2 Virus. Viruses. 2023;15(4):934. https://doi.org/10.3390/v15040934.

5. Tabatabai J, Ihling CM, Manuel B, Rehbein RM, Schnee SV, Hoos J et al. Viral Etiology and Clinical Characteristics of Acute Respiratory Tract Infections in Hospitalized Children in Southern Germany (2014–2018). Open Forum Infect Dis. 2023;10(3):ofad110. https://doi.org/10.1093/ofid/ofad110.

6. Zaplatnikov AL, Geppe NA, Blokhin BM, Kondyurina EG. Acute respiratory viral infections: focus severity. A brief overview. Russian Journal of Woman and Child Health. 2024;7(3):270–275. (In Russ.) https://doi.org/10.32364/2618-8430-2024-7-3-11.

7. Karlıdağ T, Bulut Y, Keleş E, Alpay HC, Seyrek A, Orhan İ et al. Presence of herpes viruses in adenoid tissues of children with adenoid hypertrophy and chronic adenoiditis. Kulak Burun Bogaz Ihtis Derg. 2012;22(1):32–37. https://doi.org/10.5606/kbbihtisas.2012.006.

8. Kushelevskaya OV, Sentsova TT, Volkov IK. The role of Chlamydia pneumoniae, Mycoplasma pneumoniae in the development of infection in children with recurrent and chronic lung diseases. Current Pediatrics. 2007;6(2):146–153. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/1069.

9. Savenkova MS, Afans’eva AA, Minasyan VS, Tyurkina SI. Treatment of frequently sick children with mixed infection. Current Pediatrics. 2011;10(4):83–88. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/647.

10. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. https://doi.org/10.1016/S0140-6736(21)02724-0.

11. Kalyuzhin OV. OM-85 in the prevention/treatment of respiratory infections and exacerbations of chronic lung diseases: selection criteria, mechanisms and evidence. Lechaschi Vrach. 2018;(3):77–82. (In Russ.) Available at: https://www.lvrach.ru/2018/03/15436933.

12. Kalyuzhin OV, Gorelov AV, Malyavin AG, Zaytsev AA, Esaulenko EV, Novak KE, Bykov AS. Efficacy and safety of bacterial lysate OM-85 in the treatment of uncomplicated acute respiratory infections: a double-blind, placebo-controlled, multicenter, randomized trial. Terapevticheskii Arkhiv. 2023;95(10):850–858. (In Russ.) https://doi.org/10.26442/00403660.2023.10.202464.

13. Reviakina VA, Astaf’eva NG, Geppe NA, Kaliuzhin OV. Updated PRIMA consensus document to assist the practicing physician. Pediatrics. Consilium Medicum. 2021;(2):109–112. https://doi.org/10.26442/26586630.2021.2.200992.

14. Kanner EV, Gorelov AV, Pechkurov DV, Maksimov ML, Ermolayeva AS. S Why do acute respiratory infections in children remain a topical problem? Peculiarities of the current, possibilities of prevention and treatment. Meditsinskiy Sovet. 2019;(17):198–206. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-198-206.

15. Agreed expert opinion of the IX International Educational Consensus on Respiratory Medicine in Pediatrics on the use of bacterial lysates in pediatric practice. Doktor.Ru. 2020;19(3):61–63. (In Russ.) Available at: https://www.elibrary.ru/alryaw.

16. Kosenko IM. Bacterial lysate OM-85 in the prevention and treatment of acute respiratory infections in frequently and long-term ill children (literature review). Children’s Medicine of the North-West. 2024;12(3):27–37. (In Russ.) https://doi.org/10.56871/CmN-W.2024.64.58.004.

17. Luss LV. Secondary immunodeficiency in children. The сlinician’s view on immunomodulators prescription. Allergology and Immunology in Pediatrics. 2018;(4):4–18. (In Russ.) Available at: https://elibrary.ru/mwduvq.

18. Bulgakova VA. On issue of immune modulators application in therapy and prevention of respiratory viral infections in children. Meditsinskiy Sovet. 2016;(17):62–67. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-56-61.

19. Karaulov AV, Kaliuzhin OV. Immunotherapy for infectious diseases: challenges and prospects. Terapevticheskii Arkhiv. 2013;85(11):100–108. (In Russ.) Available at: https://ter-arkhiv.ru/0040-3660/article/view/31403.

20. Калюжин ОВ. Острые респираторные вирусные инфекции: современные вызовы, противовирусный ответ, иммунопрофилактика и иммунотерапия. М.: МИА; 2014. 144 c.

21. Баранов АА, Намазова-Баранова ЛС, Лобзин ЮВ, Таточенко ВК, Усков АН, Куличенко ТВ и др. Острая респираторная вирусная инфекция (ОРВИ): клинические рекомендации. М.; 2022. 44 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/25_2.

22. Suárez N, Ferrara F, Rial A, Dee V, Chabalgoity JA. Bacterial Lysates as Immunotherapies for Respiratory Infections: Methods of Preparation. Front Bioeng Biotechnol. 2020;8:545. https://doi.org/10.3389/fbioe.2020.00545.

23. Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infec-tions: A systematic review and meta-analysis. Int Immunopharmacol. 2018;54:198–209. https://doi.org/10.1016/j.intimp.2017.10.032.

24. Feleszko W, Rossi GA, Krenke R, Canonica GW, Van Gerven L, Kalyuzhin O. Immunoactive preparations and regulatory responses in the respiratory tract: potential for clinical application in chronic inflammatory airway diseases. Expert Rev Respir Med. 2020;14(6):603–619. https://doi.org/10.1080/17476348.2020.1744436.

25. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018;18(3):198–209. https://doi.org/10.1097/ACI.0000000000000433.

26. De la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, del Río Navarro BE. Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico. Rev Alerg Mex. 2005;52(1):25–38. (In Spanish) Available at: https://pubmed.ncbi.nlm.nih.gov/15957470/.

27. Zagar S, Löfler-Badzek D. Broncho-Vaxom® in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec. 1988;50(6):397–404. https://doi.org/10.1159/000276020.

28. Zhu LL, Wang YH, Feng JH, Zhou Q. Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics. Drug Des Devel Ther. 2024;18:4387–4399. https://doi.org/10.2147/DDDT.S484897.

29. Jurkiewicz D, Zielnik-Jurkiewicz B. Bacterial lysates in the prevention of respiratory tract infections. Otolaryngol Pol. 2018;72(5):1–8. https://doi.org/10.5604/01.3001.0012.7216.

30. Liao JY, Zhang T. Influence of OM-85 BV on hBD-1 and immunoglobulin in children with asthma and recurrent respiratory tract infection. Zhongguo Dang Dai Er Ke Za Zhi. 2014;16(5):508–512. (In Chinese) Available at: http://www.zgddek.com/EN/abstract/abstract13367.shtml.

31. Abaturov OYe, Tokareva NM. Efficacy of the treatment for respiratory diseases in children using bacterial lysates. Child’s Health. 2015;(1):21–24. (In Russ.) Available at: https://www.elibrary.ru/tvvsuf.

32. Liu YW, Dong SH, Zhan GY, Tan HZ, Peng YQ, Wei F. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur Rev Med Pharmacol Sci. 2017;21(14):3332–3336. Available at: https://www.europeanreview.org/article/13160.

33. Dronov IA, Kovalenko EA. The use of bacterial lysate OM-85 in the treatment of acute respiratory tract infections in children (literature review). Lechaschi Vrach. 2020;(10):20–23. (In Russ.) Available at: https://www.lvrach.ru/2020/10/15437715.

34. Blokhin BM, Steshin VYu. OM-85 bacterial lysates for the treatment of acute respiratory infections in children. Prakticheskaya Pulʹmonologiya. 2017;(2):48–54. (In Russ.) Available at: https://elibrary.ru/zshjcn.

35. Sorokman TV, Moldovan PM, Popelyuk NO, Kolesnik DI, Sokolnyk ІS. Clinical and immunological efficacy of bacterial lysate OM-85 in children with respiratory tract infection. Actual Infectology. 2020;8(2):18–24. (In Ukrainian) https://doi.org/10.22141/2312-413x.8.2.2020.199731.

36. Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006;(4):CD004974. https://doi.org/10.1002/14651858.CD004974.pub2.

37. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010;6(1):5–12. https://doi.org/10.1007/s12519-010-0001-x.

38. Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr. 2007;166(4):365–376. https://doi.org/10.1007/s00431-006-0248-3.

39. Berber AC, Del-Rio-Navarro BE. Use of Broncho-Vaxom® in private practice: phase IV trial in 587 children. Clin Ther. 1996;18(6):1068–1079. https://doi.org/10.1016/s0149-2918(96)80062-2.

40. Esposito S, Bianchini S, Polinori I, Principi N. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study. Int J Environ Res Public Health. 2019;16(6):1065. https://doi.org/10.3390/ijerph16061065.

41. Esposito S, Cassano M, Cutrera R, Menzella F, Varricchio A, Uberti M. Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study. Hum Vaccin Immunother. 2022;18(6):2106720. https://doi.org/10.1080/21645515.2022.2106720.

42. De Boer GM, Żółkiewicz J, Strzelec KP, Ruszczyński M, Hendriks RW, Braunstahl GJ et al. Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. Eur Respir Rev. 2020;29(158):190175. https://doi.org/10.1183/16000617.0175-2019.

43. Esposito S, Marchisio P, Prada E, Daleno C, Porretti L, Carsetti R et al. Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection. Vaccine. 2014;32(22):2546–2552. https://doi.org/10.1016/j.vaccine.2014.03.055.

44. Esposito S, Bianchini S, Bosis S, Tagliabue C, Coro I, Argentiero A, Principi N. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Transl Med. 2019;17(1):284. https://doi.org/10.1186/s12967-019-2040-y.

45. Карнеева ОВ, Юнусов АС, Гуров АВ, Абдулкеримов ХТ, Рязанцев СВ, Карпова ЕП и др. Острый синусит у взрослых и детей: клинические рекомендации. М.; 2024. 49 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/313_3.

46. Svistushkin VM, Nikiforova GN, Zolotova AV, Stepanova VA. Using of topical bacterial lysates in modern clinical practice. Meditsinskiy Sovet. 2021;(6):49–56. (In Russ.) https://doi.org/10.21518/2079-701X-2021-6-49-56.

47. Карпова ЕП, Юнусов АС, Тулупов ДА, Карнеева ОВ, Зябкин ИВ, Полунин ММ и др. Гипертрофия аденоидов. Гипертрофия небных миндалин: клинические рекомендации. М.; 2024. 44 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/662_2.

48. Дайхес НА, Баранов АА, Лобзин ЮВ, Намазова-Баранова ЛС, Козлов РС, Поляков ДП и др. Острый тонзиллит и фарингит (Острый тонзиллофарингит): клинические рекомендации. М.; 2024. 55 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/306_3.